NASDAQ:ABMD - ABIOMED Stock Price, Forecast & News

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) posted its quarterly earnings results on Thursday, October, 31st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $0.93 by $0.10. The medical equipment provider had revenue of $204.97 million for the quarter, compared to the consensus estimate of $206.45 million. ABIOMED had a return on equity of 19.89% and a net margin of 26.92%. The firm's revenue for the quarter was up 12.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.09 EPS. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for ABIOMED.

ABIOMED will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

ABIOMED issued an update on its third quarter 2020 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $221.6-221.6 million, compared to the consensus revenue estimate of $226.68 million.

7 Wall Street analysts have issued 12 month price targets for ABIOMED's shares. Their forecasts range from $198.00 to $400.00. On average, they expect ABIOMED's stock price to reach $294.50 in the next year. This suggests a possible upside of 62.5% from the stock's current price. View Analyst Price Targets for ABIOMED.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED.

News articles about ABMD stock have trended negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ABIOMED earned a coverage optimism score of -2.5 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for ABIOMED.

ABIOMED saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 4,320,000 shares, an increase of 21.7% from the December 15th total of 3,550,000 shares. Based on an average trading volume of 806,900 shares, the days-to-cover ratio is currently 5.4 days. Approximately 9.8% of the shares of the stock are sold short. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Arista Networks (ANET), Square (SQ), Netflix (NFLX), Intuitive Surgical (ISRG), bluebird bio (BLUE) and Adobe (ADBE).

ABIOMED's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Country Trust Bank (0.24%), Rhenman & Partners Asset Management AB (0.19%), Chicago Capital LLC (0.17%), Commerzbank Aktiengesellschaft FI (0.03%), State of Alaska Department of Revenue (0.02%) and Alpine Global Management LLC (0.01%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Country Trust Bank, Meag Munich Ergo Kapitalanlagegesellschaft MBH, State of Alaska Department of Revenue and Louisiana State Employees Retirement System. Company insiders that have sold ABIOMED company stock in the last year include David M Weber and Martin P Sutter. View Insider Buying and Selling for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Alpine Global Management LLC, Commerzbank Aktiengesellschaft FI, Altman Advisors Inc., FNY Investment Advisers LLC, Kistler Tiffany Companies LLC, Nisa Investment Advisors LLC and Lenox Wealth Advisors LLC. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $181.28.

ABIOMED has a market capitalization of $8.18 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED.

The official website for ABIOMED is http://www.abiomed.com/.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]